RCC1L

Across TCGA pan-cancer cohorts, RCC1L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RCC1L data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RCC1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RCC1L expression acts as an unfavorable survival marker.

BRCA and PRAD are the cancer types where RCC1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	II,III,IV	0.358	0.889	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RCC1L–BRCA (DFS)

Open the BRCA breakdown →